Literature DB >> 29429070

A 34-year longitudinal study on long-term cardiac outcomes in DM1 patients with normal ECG at baseline at an Italian clinical centre.

Elisabetta Bucci1, Marco Testa2, Loretta Licchelli1, Alessandra Frattari2, Nadia Attalla El Halabieh2, Erica Gabriele2, Giulia Pignatelli2, Tiziana De Santis1, Laura Fionda1, Fiammetta Vanoli1, Stefania Morino1, Matteo Garibaldi1, Antonella Di Pasquale1, Nicola Vanacore3, Annalisa Botta4, Giovanni Antonini5.   

Abstract

Cardiac conduction and/or rhythm abnormalities (CCRA) are the most frequent and life-threatening complications in DM1. In order to determine prevalence, incidence, characteristics, age of onset and predictors of CCRA, CCRA progression and sudden cardiac death (SCD) in DM1, we collected ECG/24hECG-Holter data from a yearly updated 34-year database of a cohort of 103 DM1 patients without cardiac abnormalities at baseline, followed for at least 1 year. Fifty-five patients developed CCRA [39 developed conduction abnormalities (CCA) and 16 rhythm abnormalities (CRA)], which progressed in 22. Nine had SCD. Risk and incidence of CCRA amounted to 53.4 and 6.83% person-years (CCA: 37.9 and 4.8%; CRA 15.5 and 2%), respectively; risk and incidence of SCD amounted to 8.74 and 0.67% person-years, respectively. CTG expansion represented a predictor of CCRA incidence (HR 1.10, p = 0.04), CCRA progression (HR 1.28, p = 0.001) and SCD (HR 1.39, p = 0.002). MIRS progression during follow-up was associated with CCRA prevalence (OR 5.82, p = 0.004); older age and larger CTG expansion to SCD prevalence (OR 2.67, p = 0.012; OR 1.54, p = 0.005). Age of CCRA onset and CCRA progression was significantly lower in patients with larger CTG expansion and in those with MIRS progression. Age when SCD occurred was significantly lower in patients with larger CTG expansion. Amongst recorded cardiac abnormalities, both atrial flutter (OR 8.70; p = 0.031) and paroxysmal supraventricular tachycardia (OR 8.67; p = 0.040) were associated with SCD. Although all DM1patients may develop cardiac abnormalities at any time in their life, patients older than 30 years with larger CTG expansion and MIRS progression in particular should be carefully monitored via periodical ECG.

Entities:  

Keywords:  CTG expansion; Cardiac conduction and/or rhythm abnormalities; Incidence; Myotonic dystrophy type 1; Prevalence; Risk factors; Sudden cardiac death

Mesh:

Year:  2018        PMID: 29429070     DOI: 10.1007/s00415-018-8773-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  Ethnic distribution of myotonic dystrophy gene.

Authors:  T Ashizawa; H F Epstein
Journal:  Lancet       Date:  1991-09-07       Impact factor: 79.321

2.  Atrial flutter or fibrillation is the most frequent and life-threatening arrhythmia in myotonic dystrophy.

Authors:  Béatrice Brembilla-Perrot; Jérôme Schwartz; Olivier Huttin; Zied Frikha; Jean Marc Sellal; Nicholas Sadoul; Hugues Blangy; Arnaud Olivier; Sarah Louis; Pierre Kaminsky
Journal:  Pacing Clin Electrophysiol       Date:  2013-10-09       Impact factor: 1.976

3.  Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy.

Authors:  Saman Nazarian; Kathryn R Wagner; Brian S Caffo; Gordon F Tomaselli
Journal:  Pacing Clin Electrophysiol       Date:  2010-10-14       Impact factor: 1.976

4.  Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.

Authors:  J Mathieu; H Boivin; D Meunier; M Gaudreault; P Bégin
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

5.  Progression of somatic CTG repeat length heterogeneity in the blood cells of myotonic dystrophy patients.

Authors:  L Martorell; D G Monckton; J Gamez; K J Johnson; I Gich; A Lopez de Munain; M Baiget
Journal:  Hum Mol Genet       Date:  1998-02       Impact factor: 6.150

6.  Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy.

Authors:  Robert Breton; Jean Mathieu
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

7.  Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study).

Authors:  Jens Friberg; Henrik Scharling; Niels Gadsbøll; Gorm B Jensen
Journal:  Am J Cardiol       Date:  2003-12-15       Impact factor: 2.778

8.  Atrial flutter in myotonic dystrophy type 1: Patient characteristics and clinical outcome.

Authors:  Karim Wahbi; Frederic A Sebag; Nicolas Lellouche; Arnaud Lazarus; Henri-Marc Bécane; Guillaume Bassez; Tanya Stojkovic; Abdallah Fayssoil; Pascal Laforêt; Anthony Béhin; Christophe Meune; Bruno Eymard; Denis Duboc
Journal:  Neuromuscul Disord       Date:  2016-02-10       Impact factor: 4.296

9.  Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block.

Authors:  Susan Cheng; Michelle J Keyes; Martin G Larson; Elizabeth L McCabe; Christopher Newton-Cheh; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan; Thomas J Wang
Journal:  JAMA       Date:  2009-06-24       Impact factor: 56.272

10.  Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).

Authors:  Jordan T Gladman; Mahua Mandal; Varadamurthy Srinivasan; Mani S Mahadevan
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

View more
  4 in total

1.  Predictors of prognosis in type 1 myotonic dystrophy (DM1): longitudinal 18-years experience from a single center.

Authors:  Marco Mazzoli; Alessandra Ariatti; Gian Carlo Garuti; Virginia Agnoletto; Maurilio Genovese; Manuela Gozzi; Shaniko Kaleci; Alessandro Marchioni; Marcella Malagoli; Giuliana Galassi
Journal:  Acta Myol       Date:  2020-09-01

2.  Predictors of respiratory decline in myotonic dystrophy type 1 (DM1): a longitudinal cohort study.

Authors:  Marco Mazzoli; Alessandra Ariatti; Giancarlo Garuti; Virginia Agnoletto; Riccardo Fantini; Alessandro Marchioni; Giuliana Galassi
Journal:  Acta Neurol Belg       Date:  2020-07-10       Impact factor: 2.396

Review 3.  Cardiac Pathology in Myotonic Dystrophy Type 1.

Authors:  Mani S Mahadevan; Ramesh S Yadava; Mahua Mandal
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

4.  Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials.

Authors:  Matteo Garibaldi; Tommaso Nicoletti; Elisabetta Bucci; Laura Fionda; Luca Leonardi; Stefania Morino; Laura Tufano; Girolamo Alfieri; Antonio Lauletta; Gioia Merlonghi; Alessia Perna; Salvatore Rossi; Enzo Ricci; Jorge Alonso Perez; Tommaso Tartaglione; Antonio Petrucci; Elena Maria Pennisi; Marco Salvetti; Gary Cutter; Jordi Díaz-Manera; Gabriella Silvestri; Giovanni Antonini
Journal:  Eur J Neurol       Date:  2021-12-06       Impact factor: 6.288

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.